Literature DB >> 89857

A serologically detected tumour-specific membrane antigen of murine lymphomas which is not the target for syngeneic graft rejection.

G C Davey, G A Currie, P Alexander.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 89857      PMCID: PMC2009953          DOI: 10.1038/bjc.1979.155

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  5 in total

1.  The passive immunotherapy of murine leukaemia. I. The production of antisera against leukaemic antigens.

Authors:  R Motta
Journal:  Rev Eur Etud Clin Biol       Date:  1970-02

2.  Separation of the tumor rejection antigen (TSTA) from the major viral structural proteins associated with the membrance of an R-MuLV-induced leukemia.

Authors:  M J Rogers; L W Law; M Prat; S Oroszlan; E Appella
Journal:  Int J Cancer       Date:  1978-02-15       Impact factor: 7.396

3.  Estimation in sera by radioimmunoassay of a specific membrane antigen associated with a murine lymphoma.

Authors:  A Wolf; K A Steele; P Alexander
Journal:  Br J Cancer       Date:  1976-02       Impact factor: 7.640

4.  Spontaneous shedding and antibody induced modulation of histocompatibility antigens on murine lymphomata: Correlation with metastic capacity.

Authors:  G C Davey; G A Currie; P Alexander
Journal:  Br J Cancer       Date:  1976-01       Impact factor: 7.640

5.  Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumour.

Authors:  I Parr
Journal:  Br J Cancer       Date:  1972-06       Impact factor: 7.640

  5 in total
  2 in total

1.  Purification of immunoprotective tumor antigens by preparative isotachophoresis.

Authors:  T L Saunders; B D Kahan; N R Pellis
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

2.  Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer.

Authors:  H J Stauss; C Van Waes; M A Fink; B Starr; H Schreiber
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.